Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2010 - 2026)

Jazz Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $74.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 10.04% year-over-year to $74.5 million; the trailing twelve-month figure through Mar 2026 stood at $297.9 million (up 17.16% YoY), and the FY2025 full-year result was $291.1 million, up 17.37% from the prior year.
• Share-based Compensation for Q1 2026 stood at $74.5 million, up from $70.9 million in the prior quarter.
• The five-year high for Share-based Compensation was $88.1 million in Q3 2025, with the low at $50.1 million in Q1 2022.
• Average Share-based Compensation over 5 years is $62.5 million, with a median of $61.4 million recorded in 2023.
• Year-over-year, Share-based Compensation dropped 14.0% in 2023 and soared 47.46% in 2025.
• Tracing JAZZ's Share-based Compensation over 5 years: stood at $61.6 million in 2022, then declined by 14.0% to $52.9 million in 2023, then jumped by 32.58% to $70.2 million in 2024, then grew by 0.95% to $70.9 million in 2025, then rose by 5.15% to $74.5 million in 2026.
• The last three Share-based Compensation figures came in at $74.5 million (Q1 2026), $70.9 million (Q4 2025), and $88.1 million (Q3 2025), per Business Quant data.

Peer Comparison